The antitumor effect of prednimustine in vitro and in vivo.
Prednimustine is active against a wide variety of experimental tumors both in vivo and in vitro. In many of these tumor systems, prednimustine exhibits distinct advantages over a mixture of its constituents, chlorambucil and prednisolone. In vitro, a higher cell kill is obtained, and in vivo, at doses that are equally effective, prednimustine is less toxic. These differences could be connected with the different pharmacokinetic profiles found between prednimustine and chlorambucil plus prednisolone.
D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002460:Cell Line; D002470:Cell Survival / Q000187:drug effects; D002699:Chlorambucil / Q000008:administration & dosage / Q000031:analogs & derivatives*; D006224:Cricetinae; D003412:Cricetulus; D004305:Dose-Response Relationship, Drug; D006801:Humans; D051379:Mice; D009374:Neoplasms, Experimental / Q000188:drug therapy; D011238:Prednimustine / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use*; D011239:Prednisolone / Q000008:administration & dosage; D051381:Rats
D002699:Chlorambucil; D011238:Prednimustine; D011239:Prednisolone